Bowel Cancer and Biomarker Research Lab
Bowel cancer, also known as colorectal cancer, is the second most common cancer in Australian men and women. It affects 1 in 13 people. It is also Australia’s second deadliest cancer, with over 5,000 people dying each year. Early detection through screening can improve survival rates, however further research is needed to help find cures and prevent the disease.
The Bowel Cancer and Biomarker Laboratory at the Kolling Institute uses advanced technologies to study the genes and proteins responsible for bowel cancers growing and spreading. Our aim is to use a patient’s own molecular information to understand the risk of bowel cancer developing and to guide treatment options. As part of our research, we are studying how to control bowel polyp growth, which are precursors to cancer. We are doing this through diet and chemotherapy drugs.
Prof Mark P. Molloy, PhD | Lawrence Penn Chair of Bowel Cancer Research
The University of Sydney | Northern Clinical School
Faculty of Medicine and Health
Honorary Professor | Dept. Molecular Sciences, Macquarie University
Secretary | Australasian Proteomics Society
Dr Jun Li PhD
Postdoctoral Research Fellow
Dr Benita Tse
Postdoctoral Scientist
Matthew McKay - Senior Research Officer
Bharat Venkatesh Gunappa - Research Officer
Olivia Ivanoff - Research Affiliate
Paula Nissen - Visiting Student
Current bowel cancer research focuses on:
- Why and how some bowel polyps become cancers
- Which bowel tumours are likely to spread
- Molecular make-up of colorectal tumours
- Early detection of disease recurrence
Our research is facilitated by specimens from clinical projects we run including:
- Sydney 1000 bowel cancer study
- IMAP Bowel polyp study
Bowel Cancer and Biomarker Research related information
Events, News and Seminars
Researchers to join leading cancer care centres in exciting new trial
Posted on: 04 March, 2022
Researchers from the Kolling Institute and Royal North Shore Hospital will help drive a new project ..... Read more
Category: Funding support, Research Excellence
Exciting study to investigate new treatment for acute myeloid leukaemia
Posted on: 28 February, 2022
The Cancer Council NSW today announced funding for a new stem cell team at the Kolling Institute to ..... Read more
Category: Funding support, Research Excellence
New cutting-edge technology coming to the Kolling
Posted on: 09 February, 2022
The Kolling is set to be one of the first institutes in New South Wales to introduce new world-leadi..... Read more
Category: Research Excellence, World-leading technology